RYTM$92.570.54%-0.50
After Hours: 93.04+0.47 +0.51%
Rhythm Pharmaceuticals Inc (RYTM)
Date: 2026-10-30 16:00O: 93.48H: 95.60L: 91.42C: 92.57Vol: 427.7k
Rhythm Pharmaceuticals Inc stock is traded at $92.57, with a volume of 427,714. It is down -0.54% in the last 24 hours and down -2.78% over the past month. Rhythm Pharmaceuticals Inc is a commercial-stage biopharmaceutical company engaged in the development and commercialization of therapies for patients with rare neuroendocrine diseases. The company is focused on advancing its melanocortin-4 receptor (MC4R) agonists, including its main asset, IMCIVREE (setmelanotide), as a precision medicine designed to treat hyperphagia and severe obesity caused by rare MC4R pathway diseases. In addition, it has two early-stage investigational MC4R agonists in clinical development, RM-718 and bivamelagon, designed not to cause hyperpigmentation. The company is also focused on advancing potential candidates for congenital hyperinsulinism. It currently operates in two business segments: the United States, which generates maximum revenue, and International.
Previous Close:
$93.07
Open:
$93.48
24h Volume:
427,714
Relative Volume:
0.82
Market Cap:
$6.37B
Revenue:
$217.17M
Net Income/Loss:
-$202.68M
P/E Ratio:
-
EPS:
-$2.30
Net Cash Flow:
-$156.63M
1W Performance:
+3.70%
1M Performance:
-2.78%
6M Performance:
+13.78%
1Y Performance:
-17.21%
1-Day Range:
$91.42$95.60
1-Week Range:
$88.72$95.60
52-Week Range:
$74.50$122.20
Rhythm Pharmaceuticals Inc Stock (RYTM) Company Profile
Name
Rhythm Pharmaceuticals IncSector
HealthcareIndustry
BiotechnologyPhone
857-264-4280Address
222 BERKELEY STREET, BOSTON, MA, USACompare RYTM vs VRTX, REGN, MRNA, ARGX, ONC
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
RYTM Rhythm Pharmaceuticals Inc | $92.57 | $6.37B | $217.17M | -$202.68M | -$156.63M | -$2.30 |
 VRTX Vertex Pharmaceuticals Inc | $558.88 | $141.65B | $12.34B | $4.34B | $3.71B | $16.87 |
 REGN Regeneron Pharmaceuticals Inc | $927.89 | $95.53B | $14.92B | $4.42B | $3.79B | $41.04 |
 MRNA Moderna Inc | $221.72 | $88.52B | $2.23B | -$3.19B | -$1.60B | -$8.15 |
 ARGX Argen X Se Adr | $892.87 | $56.15B | $4.16B | $1.29B | $734.26M | $19.58 |
 ONC Beone Medicines Ltd Adr | $370.33 | $41.89B | $5.76B | $514.49M | $1.10B | $4.48 |
Rhythm Pharmaceuticals Inc Stock (RYTM) Upgrades & Downgrades
Rhythm Pharmaceuticals Inc Stock (RYTM) Financials Data
Revenue
Net Income
Cash Flow
EPS
Rhythm Pharmaceuticals Inc Stock (RYTM) Insider Trading
- David MeekerSep 14 '26Director
- Transaction
- Proposed Sale
- Cost
- $104.71
- #Shares
- 50,000
- Value ($)
- 5,235,500
- #Shares Total
- 0
- Meeker David PSep 14 '26President and CEO
- Transaction
- Sale
- Cost
- $102.67
- #Shares
- 50,000
- Value ($)
- 5,133,442
- #Shares Total
- 239,258
- Smith Hunter CAug 31 '26Chief Financial Officer
- Transaction
- Option Exercise
- Cost
- $25.79
- #Shares
- 57,187
- Value ($)
- 1,474,853
- #Shares Total
- 176,798
- HUNTER SMITHAug 31 '26Officer
- Transaction
- Proposed Sale
- Cost
- $107.17
- #Shares
- 62,774
- Value ($)
- 6,727,490
- #Shares Total
- 0
- Smith Hunter CAug 31 '26Chief Financial Officer
- Transaction
- Sale
- Cost
- $105.46
- #Shares
- 62,774
- Value ($)
- 6,619,913
- #Shares Total
- 114,024
- Shulman JosephAug 13 '26Chief Technical Officer
- Transaction
- Sale
- Cost
- $119.75
- #Shares
- 5,079
- Value ($)
- 608,210
- #Shares Total
- 15,915
- Garfield AlastairAug 13 '26Chief Scientific Officer
- Transaction
- Sale
- Cost
- $117.57
- #Shares
- 7,763
- Value ($)
- 912,703
- #Shares Total
- 2,295
- Shulman JosephAug 13 '26Chief Technical Officer
- Transaction
- Option Exercise
- Cost
- $6.80
- #Shares
- 2,024
- Value ($)
- 13,763
- #Shares Total
- 20,994
- JOSEPH J SHULMANAug 13 '26Officer
- Transaction
- Proposed Sale
- Cost
- $117.60
- #Shares
- 5,079
- Value ($)
- 597,290
- #Shares Total
- 0
- Jennifer Kayden LeeAug 13 '26Officer
- Transaction
- Proposed Sale
- Cost
- $117.60
- #Shares
- 75,834
- Value ($)
- 8,918,078
- #Shares Total
- 0
